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Some of the People, Some of the Time
Susceptibility to Acute Rheumatic Fever
Penelope A. Bryant, MA, BM BCh, MRCP, MRCPCH, PhD;
Roy Robins-Browne, MB BCh, PhD, FASM, FRCPA, FRCAPath;
Jonathan R. Carapetis, MB BS, FRACP, PhD;
Nigel Curtis, MA, MBBS, MRCP, DTM&H, PhD
Abstract—Acute rheumatic fever is a major cause of heart disease in large parts of the world, but it remains unknown why
only a small fraction of those who are infected with rheumatogenic group A streptococci develop an abnormal immune
response that leads to acute rheumatic fever. An understanding of the mechanisms underlying host susceptibility can
provide important insights into pathogenesis that in turn can inform new treatments. Extensive searches for susceptibility
factors have been undertaken, including human leukocyte antigens, B-cell alloantigens, and cytokine genes. Although
significant associations have been found between genetic factors and acute rheumatic fever, study results often conflict
with each other. This review explores current understanding about host susceptibility to acute rheumatic fever and
provides an overall perspective to the number of studies that have recently addressed this subject. (Circulation. 2009;
119:742-753.)
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Acute rheumatic fever (ARF) remains a major cause ofheart disease and premature death in large parts of the
world (Figure 1). ARF is a systemic inflammatory autoim-
mune disease that follows throat infection with Lancefield
group A -hemolytic streptococci (Streptococcus pyogenes).
The pathogenesis of ARF is believed to involve the triad of a
genetically susceptible individual, infection with a rheumato-
genic strain of group A streptococcus, and an aberrant host
immune response. There have been excellent recent reviews
addressing group A streptococcal virulence28 and the immuno-
pathogenesis of ARF.29 A key question that remains unanswered
is why only a small fraction of those infected with rheumato-
genic group A streptococci develop an abnormal immune
response that leads to ARF.
An understanding of the mechanisms underlying host
susceptibility can provide important insights into pathogene-
sis that in turn can inform new treatments and vaccine
development. The identification of individuals susceptible to
ARF would also help in the diagnosis of ARF. Currently, the
Jones criteria are not very sensitive or specific in countries
with a high incidence, and a test for susceptibility would
increase specificity. An appreciation of host susceptibility is
increasingly important with the imminent arrival of new
group A streptococcal vaccines that may offer protection
against ARF.30–32 The present review explores current under-
standing about host susceptibility to ARF and provides an
overall perspective to the number of studies that have recently
addressed this subject.
Epidemiological Support for a Hereditary
Susceptibility to ARF
The role of host factors in ARF is supported by the observa-
tion that different clinical outcomes occur during an outbreak
of a single rheumatogenic group A streptococcal strain.33,34 In
populations exposed to rheumatogenic group A streptococci,
the lifetime cumulative incidence of ARF is remarkably
constant at 3% to 6%.23 This is regardless of geography or
ethnicity and suggests a strong genetic component to ARF
susceptibility. Rates of ARF similar to those found in devel-
oping countries today were documented in industrialized
countries during the early to mid 20th century.35 In most of
those countries, ARF has now become rare, yet the genetic
makeup of their populations has not changed dramatically.
Susceptible individuals are still present, but they are no
longer being exposed to rheumatogenic group A streptococci
as a result of factors such as living conditions.
Early studies showed a family predilection for ARF.36,37 As
far back as 1889, Cheadle36 noted that the chance of an
individual with a family history of ARF acquiring the disease
is “nearly 5 times as great as that of an individual who has no
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such hereditary taint.” A more recent cohort study of children
raised separately from their parents in an Israeli kibbutz
showed that children whose parents had rheumatic heart
disease (RHD) had a relative risk of 2.93 for the development
of ARF compared with children whose parents did not have
RHD.37 An inherited susceptibility to ARF and RHD is
supported by twin studies that have found a significantly
increased concordance in monozygotic twins compared with
dizygotic twins38,39; however, the lower than expected con-
cordance (3 of 16 pairs) in these studies indicates that it is not
simple mendelian single-gene inheritance. The search for sus-
ceptibility genes has been vigorous.
Human Leukocyte Antigens
As critical components in antigen processing, the major
histocompatibility complex human leukocyte antigen (HLA)
molecules are attractive candidate antigens that might confer
susceptibility to ARF. HLA class II molecules in particular
are associated with other autoimmune diseases (for example,
HLA-DR2 and systemic lupus erythematosus and HLA-DR3
and insulin-dependent diabetes mellitus).
In general, HLA class II molecules appear to have a closer
association with increased risk of ARF or RHD than class I
molecules, although no single HLA haplotype or combination
exists that is consistently associated with susceptibility
(Table 1). Similarly, intensive study of the DR locus in a
Brazilian population showed an association with RHD but
failed to find either a specific allele or unique nucleotide
sequence that conferred susceptibility.68 The authors pos-
tulated that this might be due to either the cross-reacting
peptide being indiscriminate or heterogeneity of the caus-
ative agent. Although most interest has been focused on
association with increased risk, several HLA molecules
have been found to be associated with decreased risk of
ARF.40,45,46,48,52,53,58 – 61,63,64,67
A wide variation exists in results of studies in different
geographic regions and ethnic populations, as well as incon-
sistent findings between different studies in similar popula-
tions. Some of the differences may be attributable to the
technique used for HLA typing. Earlier studies that used
serological methods are subject to potential inaccuracies and
are unable to distinguish between allelic subgroups; however,
results from more recent molecular studies that have
investigated allelic subgroups have also found differences
between ethnic groups, both in alleles and in haplo-
types.50,59 – 61,63,64,66,67 Another potential source of variabil-
ity between studies is the selection of control subjects.
Where historical controls have been used, these may not be
representative of the population from which the case
subjects came. It is also possible that differences in clinical
classification of ARF and RHD between studies are responsible
for some of the different results. Some support can be seen for
this in the finding that HLA associations are stronger in more
clinically homogenous patients.47,57,63 Also, some studies have
found HLA associations only with particular clinical features of
ARF; for example, in 1 study, a significant association was
found between HLA-A10 and HLA-DR11 in patients with
cardiac manifestations compared with ARF without cardiac
features, the latter group having a higher frequency of HLA-
C2.42 However, even with disease defined in exactly the same
way, ethnic differences in HLA association are apparent,47
which supports a genuine ethnicity-specific genetic susceptibil-
ity. Overall, most studies support the notion of an HLA associ-
ation with ARF/RHD.
The mechanism of HLA association is unknown. One
theory is that similarity exists between antigens from rheu-
matogenic group A streptococcal strains and HLA molecules.
If antigens from different strains of bacteria were structurally
similar to different HLA molecules, this would result in an
increased proportion of individuals of a specific HLA type
with ARF during an outbreak or in a geographic population
where a particular streptococcal strain dominates. To date, no
study has investigated people from 1 ethnic group who have
moved to a geographic area with a different predominant
Figure 1. Worldwide prevalence of RHD. Rates (in parentheses) are based on studies in school-age children unless indicated by
an asterisk, in which case, they include adults. a, United States* (0.02)1; b, Native American* (4.6)2; c, Cuba (2.9)3; d, Brazil (3.6)4;
e, Bolivia (7.9)5; f, Mali (3.8)6; g, Côte d’Ivoire (1.9)7; h, Egypt (5.1)5; i, Sudan (10.2)5; j, Ethiopia (6.4)8; k, Kenya (2.7)9; l, DPR
Congo (14.3)10; m, Zambia (12.5)11; n, South Africa (1.0)12; o, Soweto, South Africa (6.9)13; p, Turkey (3.7)14; q, Saudi Arabia
(2.4)15; r, Yemen (3.6)16; s, Bikaner, India (16.7)17; t, India (3.0)18; u, Nepal (1.2)19; v, Bangladesh (1.2)20; w, Sri Lanka (6.0)21;
x, China* (1.9)22; y, Philippines (1.6)6; z, Aboriginal Australian (6.8)23; A, Maori New Zealand (6.5)24; B, non-Maori New Zealand
(0.9)24; C, Samoa (77.8)25; D, Tonga (2.7)26; E, Cook Islands (18.6)27; and F, French Polynesia (8.0).27
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Table 1. HLA Associations With ARF/RHD in Different Countries and Ethnic Populations
HLA Antigen Association Lack of Association Method Disease Country/Ethnicity No. in Study
Year and
Reference
HLA class I
A33 1 Rest of A, B S ARF/RHD North India 134 198640
A19 1 Rest of A, B, C S RHD Kashmir 54 199741
A10 1 Rest of A, rest of B, C, DR S ARF Turkey 100 199342
B35 1
B5 2 Rest of B, A, C S RHD Kashmir 50 199743
B35 1 Rest of B, A, C S ARF Martinique 88 198644
B14 2
B42 2
B16 1 Rest of B, A S RHD Turkey 107 199345
B51 2 Rest of B, A M RHD Turkey 85 200746
Cw*4 2 Rest of C
HLA class II DR
DR2 1 Rest of DR, A, B, C S ARF/RHD, especially with
cardiac features
USA: black 48 198647
DR4 1 USA: white 24
DR4 1 Rest of DR S RHD USA: white 33 198648
DR6 2
DR1-9    DR1-9 S RHD USA: white 57 1995
49
DR4    DR4 M
DRB1*16 1 Rest of DRB1 M ARF USA: white 33 199850
DR1 1 Rest of DR S ARF Martinique 88 198644
DR1 1 Rest of DR, A, B, DQ S Severe RHD Black South Africans 103 198751
DR6 1
DR3 1 Rest of DR S ARF/RHD North India 134 198640
DR2 2
DR2 2 Rest of DR, A, B S RHD North India 52 198952
DR2 2 Rest of DR, A, B, C S RHD North India 165 199053
DR3 1
DR4 1 Rest of DR, DQ S RHD Kashmir 54 199741
DR4 1 Rest of DR, DQ S RHD Kashmir 50 199743
DR4 1 Rest of DR, A, B, C S ARF/RHD Saudi Arabian Arabs 40 198754
DR7 1 Rest of DR1 10, DR52, A, B, DQ S ARF/RHD Brazil: white/light
mulatto
40 199155
DR53 1 37
DR7 1 DR53 S ARF/RHD Brazil: white 35 200056
DR4 1 Rest of DR, A, B S ARF, especially with
cardiac features
Turkey 93 199257
DR3 1 Rest of DR S RHD Turkey 107 199345
DR7 1
DR5 2
DRB1*01 2 Rest of DR M RHD Turkey 85 200746
DRB1*04† 2 Rest of DRB1 M ARF Turkey 55 200558
DRB1*13 2 Rest of DRB1, A, B, C, DRB4 DQB1 M RHD Turkey 100 200659
DRB3 2
DRB5 2
DRB1*07 1 Rest of DRB1*01-*18 M RHD Latvia 70 200360
DRB1*06 2
DRB1*07‡ 1 DRB1: 5 alleles M RHD Turkey 102 200661
DRB1*11 2
(Continued)
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streptococcal type. This theory is supported by a study in a
population in which HLA-DR4 was associated with ARF.69
The investigators found that antistreptococcal serum caused
significantly increased toxicity to B lymphocytes bearing
HLA-DR4 compared with DR4-negative lymphocytes, and
they suggested that a strong antigenic similarity existed between
HLA-DR4 and the streptococcal antigen, which led to defective
antigen presentation by the HLA molecule (Figure 2). This in
turn could lead to aberrant cytokine production and ultimately
antibody formation against proteins on valves, myocardium,
brain, and joint tissue.71 However, this occurred in lympho-
cytes both from individuals with ARF/RHD and from control
subjects, which left the progression to ARF in some individ-
uals unexplained. This study has not been repeated with any
other HLA types. An alternate theory is that structural
similarity causes streptococcal antigens to mimic HLA mol-
ecules, which initiates an aberrant immune response.70
More recently, it has been suggested that after binding to
the antigenic peptide, the particular HLA complexes may
initiate inappropriate T-cell activation72 (Figure 2). In this
model, the HLA complex on the surface of the antigen-pres-
enting cell presents the streptococcal peptide to peripheral T
cells that have escaped immune tolerance. These T cells
recognize and are activated by the peptide, but then they
cross-react with similar self-antigens that they are unable to
identify as self, which initiates the autoimmune process. This
concept of an autoimmune process that is initiated by HLA-
specific antigen presentation is supported by a recent study
that used T-cell lines from valves of patients with severe
RHD.72 In that study, an immunodominant peptide of the
streptococcal M5 protein bound to HLA-DR53 and was
recognized by an infiltrating T-cell clone from an HLA-
DR53–positive RHD patient, which suggests that the peptide
is presented to T cells in the context of HLA-DR53 in this
instance.
The fact that different ethnic groups with ARF/RHD may
have different HLA associations suggests that cross-reactive
peptides may bind to several different HLA alleles that have
structural homology in the peptide-binding groove. Although
not inconsistent with this model, most researchers, however,
have concluded that the association between HLA and ARF/
RHD is through linkage disequilibrium and that an ARF
Table 1. Continued
HLA Antigen Association Lack of Association Method Disease Country/Ethnicity No. in Study
Year and
Reference
DRB1*07 1 DQA1, DQB1 M RHD Pakistan 114 200762
DRB1*0701 1 Rest of DRB1 M RHD, especially with
similar clinical features
Egypt 88 199963
DR16
(DRB1*1602)
1 Rest of DR, DQA1, DQB1 M RHD Mexico 98 200364
DR11 2
DRB1    DRB1: 13 alleles M ARF Italy 25 2004
65
HLA class II DQ
DQ2§ 1 Rest of DQ S RHD North India 52 198952
DQA1    DQA1 M RHD USA: white 57 1995
49
DQB1    DQB1
DQA1*0104 1 Rest of DQA1 and DQB1, DRB1,
DPA1, DPB1
M RHD Japan 72 199666
DQB1*05031 1
DQA1*0101 1 Rest of DQA1 M ARF/RHD South China 54 199767
DQA1*0102 2
DQA1*0201 1 Rest of DQA1, DQB1 M RHD, especially with
similar clinical features
Egypt 88 199963
DQA1*0103 2
DQB1*0603 2
DQB1*302 1 Rest of DQB1 M RHD Latvia 70 200360
DQB1*0401-2 1
DQB1*0501 2
DQB1*0602-8 2
DQA1*03 2 Rest of DQA1, DQB1 M ARF Turkey 55 200558
DQB1*08 1 Rest of DQ M RHD Turkey 85 200746
S indicates serological; M, molecular.
†Only in combination with DQA1*03.
‡Association also found with recurrent streptococcal pharyngitis.
§Only in D8/17-positive patients.
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susceptibility gene exists that is mapped within or near the
HLA complex. This may explain ethnically defined differ-
ences. A cosegregation study of 22 families of different
ethnic background with multiple individuals with RHD sup-
ported this hypothesis, concluding that the inheritance
method was dominant with variable penetrance.74 This sup-
ports the original twin-study finding of lower than anticipated
concordance in monozygotic twins.39
B-Cell Alloantigens
The idea that genetic determinants within the host immune
response may be relevant to susceptibility to ARF led
Patarroyo et al75 to use B-cell antiserum to distinguish
individuals with past ARF from control subjects. Using
alloantisera, they identified a novel B-cell alloantigen,
called 883, which was expressed on the B cells of 71% to
74% of rheumatic fever patients compared with only 17%
of control subjects.75 Monoclonal antibodies were devel-
oped to the alloantigen by Zabriskie et al76 and subse-
quently to another B-cell surface antigen that more accu-
rately identified ARF patients.77 A number of studies have
investigated the association of this antigen, D8/17, and
ARF (Table 2).
In some studies, results have been expressed as the per-
centage of B cells that stain positive for the D8/17 antigen. In
others, a receiver operator curve or other method has been
Figure 2. Possible mechanisms for HLA
association with ARF. The left side of the
figure (antibody theory) illustrates how
antibodies may be central to the mecha-
nism through which the HLA association
is mediated, either through defective pre-
sentation by the HLA molecule because
of antigenic similarity,69 or through strep-
tococcal antigens mimicking the HLA
molecule.70 This is proposed to lead to
aberrant cytokine production, poor anti-
genic clearance, prolonged B cell stimula-
tion and increased production of antibod-
ies against the various tissues affected in
ARF.71 The right side of the figure (antigen
theory) illustrates how streptococcal anti-
gens may be presented to T cells in the
context of specific HLA molecules, which
are cross reactive to epitopes on the tis-
sues affected in ARF, initiating an aber-
rant T cell response.72,73 GpA indicates
group A; TCR, T-cell receptor.
Table 2. Results of D8/17 Studies in ARF/RHD in Different Countries and Ethnic Populations
Proportion of
Individuals
Positive (%)
Proportion of B Cells Staining Positive
for D8/17 (Mean %1 SD)
Country/Ethnicity Patients Controls Patients Relatives Controls
Cutoff (% B Cells
Stained) Disease
No. of RHD Cases
in Study
Year and
Reference
United States and Trinidad 98.8 14 33.58.5 13.75.8 7.54.3 11.8 RHD 84 198977
North India 62.9 12.5 RHD 54 198952
North India 66.4 14 40 RHD 90 199278
North India 68.8 14 10 ARF/RHD 63 199879
Mexico 89.7 11.1 34.613.2 12.55.7 7.56.9 14.4 ARF/RHD 39 199080
Brazil 90 0 38.817.8 16.29.4 4.62.8* 12 RHD 10 199281
Russia 88.9 10 ARF/RHD 117 199182
Russia 24.80.4† 11.11.0† ARF/RHD 40 199683
Israel 91 0 11.53.0 4.22.7 7.55 ARF 22 200284
Aboriginal Australian 94.7 4.4 39.311.8 22.55.2 11.67.3 22.1 ARF/RHD 41 200685
*Estimated SE.
†Insufficient data available to confirm SE.
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used to find a cutoff that is subsequently used to classify
individuals as either positive or negative. With both methods,
a clear difference has been shown in the expression of this
antigen between RHD and control patients (Figure 3). How-
ever, substantial differences exist between studies in the
proportion of D8/17-positive B cells; for example, a study in
Israel84 reported the same mean percentage of D8/17-positive
B cells (11%) in the disease group as was documented in the
control groups in studies in Russia83 and Australia.85 Whether
this is a difference between study methodology or expression
in different populations remains unresolved. Regardless,
D8/17 antigen appears to be more robust than HLA typing as
a marker for RHD in geographically and ethnically diverse
populations.
D8/17 appears to be more than merely a marker of past or
current disease. In first-degree relatives, the proportion of
D8/17-positive cells or individuals classified as positive has
been found to lie between the proportions measured in
patients and control subjects with no family history of RHD
(Table 2).77,80,81,85 Khanna et al77 showed that D8/17 expres-
sion in healthy siblings of index case subjects depended on
their parents’ D8/17 results. The authors suggested that the
D8/17-positive phenotype is an inherited trait, possibly auto-
somal recessive with incomplete penetrance. An intriguing
finding in a study of family members of individuals with
RHD was that 1 unaffected sibling with a high level of
positive B cells (30% positive, with 13% being the proportion
of D8/17-positive B cells that discriminated between rheu-
matic and nonrheumatic individuals) developed ARF shortly
afterward.86 This supports the hypothesis that it is a true
marker of susceptibility, which makes it an attractive prospect
for identifying potential recipients of a vaccine or early
preventative antibiotics.
Expression of D8/17 in patients with acute disease was
recently studied in Aboriginal Australians.85 A small number
of individuals with ARF had a significantly higher proportion
of D8/17-positive cells (83.710.1%) than individuals with
RHD (39.311.8%), who in turn had a higher proportion
than relatives (22.55.2%), with healthy control subjects
having the lowest proportion (11.67.2%; ANOVA between
means P0.001). The authors hypothesized that D8/17 was
expressed in susceptible patients and that this was augmented
by the process that leads to ARF.
Infectious stimuli such as pneumonia and gastroenteritis
have not been associated with increased D8/17 expression,
which suggests that D8/17 is not a nonspecific result of B-cell
activation.84 Studies showing an increasing percentage of
D8/17-positive B cells with age in both individuals with
RHD78 and their relatives86 suggest that expression may be a
result of cumulative exposure to group A streptococcal
antigens. However, in the Aboriginal population in northern
Australia, where infection with group A streptococci is
endemic, D8/17 expression was higher in relatives than in
control subjects, which suggests that inheritance is a more
important factor than exposure to streptococci.85 D8/17 ex-
pression appears to be specific to rheumatic fever, because no
association is present with other diseases such as poststrep-
tococcal glomerulonephritis, rheumatoid arthritis, or systemic
lupus erythematosus.77,87 However, a recent finding that 19
patients with poststreptococcal reactive arthritis had higher
D8/17 expression than control subjects puts this into question
once again.88 It may suggest a shared genetic susceptibility
with ARF, but it could also support the streptococcal expo-
sure theory.
Most studies have reported D8/17-positive expression in
85% of individuals with previous ARF, but this is not
universal.52,78,79,89 In 1 study, antibodies to D8/17 were only
found to discriminate between ARF patients and control
subjects when staining of total lymphocytes (B and T cells)
was assessed, which led to the authors’ suggestion that the
discriminatory nature of D8/17 found in previous studies is
simply a measure of B-cell numbers.89 In studies in which it
is not explicitly stated that only B cells were stained, this is a
possibility; however, in studies in which it is clear in the
methods that staining for D8/17 was only undertaken in B
cells,85 the discriminatory nature of D8/17 is unambiguous.
Inconsistencies in the results between D8/17 studies have also
been ascribed to technical difficulties with the D8/17
antibody.90
Differences between studies are more likely to be attribut-
able to population differences in B-cell alloantigen expres-
sion. In several studies in northern India, the proportion of
patients with RHD who were D8/17 positive was only 63% to
69%.52,78,79 Monoclonal antibodies (PG-12A, -13A, and
-20A) were therefore developed against B-cell alloantigens in
local patients with ARF/RHD. In combination, these antibod-
ies identified 90% of north Indian patients with ARF/RHD
and were better than antibodies to D8/17 at discriminating
between RHD patients and control subjects.79 Like D8/17,
these population-specific B-cell alloantigens are most highly
expressed in ARF but remain positive in chronic RHD.91 This
study also showed that the proportion of D8/17-positive cells
in ARF diminished between the acute phase and 3-month
follow-up. It is not known whether the best way to discrim-
inate patients with ARF/RHD from control subjects in every
population is to use D8/17 or other monoclonal antibodies
directed against markers in the local population.
Figure 3. Proportion of D8/17-positive B cells in studies in ARF/
RHD in different countries and ethnic populations. Error bars
represent SEM.
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It is not clear whether or how the expression of these
alloantigens on B cells relates to the host immune response to
group A streptococci. Williams et al92 showed that the
monoclonal antibody binds to sites on the surface of reactive
B cells very close to but distinct from sites that bind group A
streptococcal membrane antigens. This suggests a close
relationship between them, possibly involving recognition
and binding. A study on the tissue distribution of D8/17
antigen showed strong expression in cardiac, skeletal, and
smooth muscle in blood vessels, as well as various epithelial
and hepatic tissues.93 In the same study, a monoclonal
antibody to D8/17 bound to vimentin and myosin (cardiac
proteins) and to recombinant streptococcal M protein. This
suggests shared epitopes between the proteins, alluding to a
potential role in pathogenesis. It is possible that D8/17 could
be an anti-idiotype, mimicking the antigenic interaction with
antibodies and T cells in ARF. The same group also showed
that cells from the pathognomonic rheumatic fever Aschoff
nodule expressed both HLA-DR and D8/17.94 However, no
correlation has been found between the presence of D8/17
and clinical outcome, and any role it may have in pathogen-
esis remains uncertain.84
Immune Gene Polymorphisms
There have only been a limited number of studies investigat-
ing genetic susceptibility associated with other components
of the immune response (Table 3). In most cases, these
comprise single studies in 1 population. However, there have
been several studies examining the role of polymorphisms in
the promoter region of the tumor necrosis factor- (TNF-)
gene. These have shown associations with RHD in Mexican
patients, both in the allele (TNF--308A and -238G) and in
the genotype.95 An association was also found with valve
damage, but no relationship was found with the specific valve
Table 3. Associations With Immune Gene Polymorphisms and ARF/RHD
Immune Gene Allele Association Disease Country/Ethnicity No. in Study Year and Reference
Cytokine genes
TNF- promoter 308A 1 RHD Mexico 87 200395
1 ARF/RHD Turkey 71 200596
1 ARF/RHD Brazil 318 200697
None ARF Turkey 66 200698
1 RHD Egypt 50 200799
308G 2 RHD Mexico 87 200395
None ARF Turkey 66 200698
238G 1 RHD Mexico 87 200395
238A 2 RHD Mexico 87 200395
1 ARF/RHD Brazil 318 200697
TGF-1 509C* 2 RHD Taiwan 115 2004100
869T 1
IL-1Ra I/II/IV None RHD Taiwan 115 2005101
Intron 2 1 RHD Egypt 50 200799
IL-10 C/A None RHD Taiwan 115 2005101
1082A 1 RHD Egypt 50 200799
1082G 1 RHD Egypt 50 200799
IL-1 promoter C/T None RHD Taiwan 115 2005101
IL-1 E1/E2 None 115 2005101
IL-4 promoter C/T None 115 2005101
IL-4 RP1/RP2 None 115 2005101
IL-6 174G/C None RHD Egypt 115 2005101
Other immune genes
FcRIIA R131 1 ARF Turkey 66 2004102
FcRIIIB NA1/NA2 None
TCR C/V None RHD New Zealand: white and Maori 98 1995103
TCR V7/V8 None
TLR 753Gln 1 ARF Turkey 61 2005104
753Arg 2
677Arg/Trp None
TNF indicates tumor necrosis factor; TGF, transforming growth factor; IL, interleukin; IL-1Ra, IL-1 receptor antagonist; TCR, T-cell receptor; and
TLR, Toll-like receptor.
*Only significant as CC genotype.
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affected.95 A study in Turkey confirmed the TNF--308A
polymorphism association in RHD and showed that these
patients also had increased production of TNF- compared
with those with the TNF--308G allele.96 A recent study in
Brazil confirmed that patients with ARF/RHD were more
likely to have the TNF--308A polymorphism,97 but an
Egyptian study99 found that this was only true in individuals
homozygous for the TNF--308A allele; heterozygous A/G
genotypes were significantly less common in patients with
RHD.99 An association with the TNF--238 polymorphism
was also found, but in this population,99 it was with the
TNF--238A allele rather than the G allele found in Mexican
patients.95 In addition, when patients were clinically stratified
in the Egyptian study,99 the polymorphisms were found to be
present in patients with RHD and valvular lesions but not in
those with Sydenham’s chorea. One study in Turkish children
showed no association between polymorphisms in the TNF-
gene and risk of ARF or disease progression.98 However, in
general, there does appear to be a risk association with
polymorphisms in the TNF- promoter region. Although
cytokines are thought to play a role in ARF, the TNF- gene
maps close to the major histocompatibility complex region,
and as yet, it is unclear whether the association is related to
the effects of TNF- or linkage disequilibrium with HLA or
other possible risk-associated genes. If it is a marker for
development of particular clinical features, as has been
suggested, there may be therapeutic implications.97
Noncytokine components of the immune response have
received less attention. One study found associations between
immunoglobulin FcRIIA gene polymorphisms and concom-
itant genotypes in susceptibility to ARF.102 A possible mech-
anism for the association is a genetically determined failure
of removal of immune complexes. Circulating immune com-
plexes previously have been found in the sera of RHD
patients along with raised IgG.58 Conversely, no association
was found between RHD and polymorphisms in the T-cell
receptor - and -chains in a study in Caucasian and Maori
populations.103 The discovery of Toll-like receptors (TLR),
key components of the innate immune response to bacteria,
has introduced new avenues for research in disease associa-
tions. The only TLR polymorphism to be studied in relation
to ARF/RHD to date, TLR-2, showed a strong association
with ARF in children.104
Other Gene Associations
Familial Mediterranean fever is an inflammatory condition
characterized by recurrent fever, abdominal pain, and arthritis
that is caused by mutations in the MEFV gene that encodes
pyrin. Polymorphisms in the MEFV gene are associated with
a number of inflammatory conditions, including juvenile
rheumatoid arthritis105 and psoriatic arthritis.106 Patients with
familial Mediterranean fever have a higher prevalence of
RHD than the general population,107 and polymorphisms in
the MEFV gene are associated with ARF.108 However, a
recent study found that the polymorphisms in the TNF-
promoter region that are associated with ARF are not asso-
ciated with familial Mediterranean fever, which suggests the
association is by an alternate mechanism.109 The most con-
sistent feature in all of these diseases is arthritis, and in
rheumatoid arthritis, MEFV mutations are associated with
more severe joint symptoms.110 It has been suggested that
MEFV polymorphisms cause impaired control of the type 1
helper T cell (Th1) immune response, which is consistent
with the proposed pathogenesis of ARF.
Most studies have investigated gene associations with
susceptibility to ARF rather than disease severity; however,
polymorphisms of the ACE gene have recently been associ-
ated with chronic valvular fibrosis and calcification in
RHD.111,112 These polymorphisms are strongly associated
with valvular damage compared with individuals with previ-
ous ARF but normal valves.113
Genetically Determined Host
Responses in ARF
Despite the burgeoning number of studies, it remains uncer-
tain whether the associations between ARF/RHD and HLA
molecules, B-cell alloantigens, and immune and other gene
polymorphisms have a role in pathogenesis or simply repre-
sent disease markers. Although the molecular pathogenesis
and immunopathogenesis of ARF have been explored in
extensive detail,29,114 there has been less work to date at-
tempting to link the potential susceptibility factors described
above with current knowledge about pathogenesis. Defining
the role of susceptibility factors in pathogenesis will allow us
to understand more than the mode of inheritance of ARF.
Recent studies of the pathogenesis of other severe strepto-
coccal diseases hint at how host genetic susceptibility might
influence disease outcome. It is well described that the same
invasive streptococcal strain can cause disease of varying
severity in different individuals.115 Certain HLA types protect
individuals against severe invasive disease caused by supe-
rantigens, whereas others confer susceptibility.116,117 More-
over, different combinations of HLA allelic variations pres-
enting different superantigens result in different in vitro
proliferative effects and production of cytokines.117 This has
been further explored in a study that showed that binding of
the superantigen streptococcal pyrogenic exotoxin B is de-
pendent on an HLA-DQ -chain polymorphism, which went
on to show this affected T-cell proliferation and cytokine
production.118 In a mouse model, genetic differences affected
the deposition of anti-myosin autoantibodies and the subse-
quent development of myocarditis.119 Whether any of these
mechanisms are involved in the pathogenesis of ARF is not
known.
In a disease as complex as ARF, which involves different
potential bacterial antigenic triggers, humoral and cellular
arms of the immune response, and damage to multiple
specific tissues, it is doubtful that a single gene holds the key
to understanding the intricacies of its pathogenesis. This
complexity is underlined by the fact that although strong
associations exist between susceptibility and disease, geneti-
cally susceptible individuals (defined by a previous episode
of ARF) do not invariably develop ARF after exposure to
rheumatogenic strains of group A streptococci.120 The advent
of microarray technology has provided an ideal tool for the
investigation of complex diseases such as ARF/RHD through
the global analysis of genes and gene expression. To date,
there have been no studies analyzing the entire host genome
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in relation to susceptibility to ARF/RHD. There have, how-
ever, been 4 global gene expression studies that investigated
the host response to group A streptococci; 2 of these studies
analyzed gene expression in human cells after stimulation
with the bacteria in vitro, and 2 investigated gene expression
in vivo in mice.
A comparison of gene expression responses in neutrophils
after in vitro stimulation with various bacteria showed that
group A streptococci induce a unique gene expression profile
in addition to the changes induced by all bacteria.121 Phago-
cytosis of group A streptococci caused differential expression
of 393 genes in neutrophils that differed significantly from
those induced by other bacteria. These included altered
expression of 71 genes involved in apoptosis and cell fate and
26 genes regulated by interferon-. The authors postulated
that as a result of decreased neutrophil survival, this favors
pathogen survival and consequently the likelihood of disease.
Pharyngeal adherence by rheumatogenic group A strepto-
cocci is thought to be a necessary virulence mechanism in the
pathogenesis of ARF. A study of gene expression in human
epithelial cells after in vitro stimulation with M49 group A
streptococci (a nephritogenic strain) found that the Fas-2
component signal transduction system induces massive cyto-
kine gene expression, apoptosis, and cytotoxicity.122 The
response induced by a rheumatogenic strain has not been
investigated, but it would be interesting to determine whether
differences in immune response exist at this early stage of
infection that might explain rheumatogenicity.
Macrophages are part of the cellular infiltrate in acute
valvular disease in ARF, which implies their involvement in
the pathogenesis of the disease.94 Investigation of murine
peritoneal macrophages after in vivo peritoneal injection of
group A streptococci revealed a gene expression pattern that
did not contain all components of either the classic or the
alternative pathway of macrophage activation, although it
reflected both.123 Upregulation of phagocyte oxidase led the
authors to propose that this might mediate phagocytic killing
of the bacteria, which was confirmed in subsequent experi-
ments with knockout mice. Animal arthritis models have been
used to investigate inflammatory and autoimmune processes.
In a study in which cell-wall antigen from group A strepto-
cocci was injected into rat joints in vivo, analysis of total
RNA from the synovial fluid showed upregulation of genes
involved in chemotaxis and the inflammatory response.124 In
addition, 10 genes were upregulated that had not previously
been associated with arthritis, and these were found to map to
genomic loci associated with autoimmune diseases, such as
systemic lupus erythematosus and multiple sclerosis. Al-
though these studies provide tantalizing clues to pathogen-
esis and autoimmunity, to date, no studies have been
published that have used microarrays to investigate ARF or
RHD.41,43,44,49,51,54 –56,62,65,82,100,101
The series of immunologic events that occur in a suscep-
tible individual when infected with rheumatogenic group A
streptococci but do not occur in a nonsusceptible individual
remain to be fully delineated. Future research should include
large studies in multiethnic populations, particularly in mi-
gratory populations, of the association between the various
genes and markers described in the present review, to
determine whether associations are primarily genetic or
geographic. In addition, it would be revealing to use global
genome analysis to investigate ARF and to determine how
host responses differ between individuals who are susceptible
and nonsusceptible. These types of studies would provide
insight into the multiple genes and other susceptibility factors
that are involved in the interplay between rheumatogenic
bacteria and the host immune system that leads to the aberrant
autoimmune response underlying the immunopathogenesis
of ARF.
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